- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.12. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.11. | Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% | 2 | Benzinga.com | ||
| 06.11. | HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 | 4 | MarketBeat | ||
| 05.11. | Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | 117 | GlobeNewswire (Europe) | - Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy -- Overall response rate (ORR) of 83%... ► Artikel lesen | |
| 05.11. | Century Therapeutics, Inc.: Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 05.11. | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Century Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.09. | Century Therapeutics Appoints Morgan Conn As CFO | - | RTTNews | ||
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.09. | Century Therapeutics taps Morgan Conn as CFO | 1 | Seeking Alpha | ||
| 26.09. | Century Therapeutics, Inc.: Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer | 125 | GlobeNewswire (Europe) | - Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy... ► Artikel lesen | |
| 26.09. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | H.C. Wainwright tracks Century Therapeutics' trial progress, lowers stock PT | 7 | Investing.com | ||
| 08.08. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates | 103 | GlobeNewswire (Europe) | - Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis... ► Artikel lesen | |
| 08.08. | Century Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Century Therapeutics, Inc.: Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting | 111 | GlobeNewswire (Europe) | In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary... ► Artikel lesen | |
| 11.04. | Century Therapeutics, Inc.: Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics | 136 | GlobeNewswire (Europe) | Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile... ► Artikel lesen | |
| 08.04. | Century Therapeutics, Inc.: Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting | 150 | GlobeNewswire (Europe) | PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in... ► Artikel lesen | |
| 14.03. | Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates | 203 | GlobeNewswire (Europe) | - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,410 | +0,06 % | Evotec, Rheinmetall, Vidac Pharma Aktie: Kaufempfehlung, Krebsrevolution oder Kurseinbruch? | Das Potenzial auf eine Vervielfachung sehen Analysten bei der Aktie von Vidac Pharma. Der Wert gehört bereits zu den Überfliegern im Biotech-Sektor im zweiten Halbjahr. Das Unternehmen will die Krebsbehandlung... ► Artikel lesen | |
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,923 | -0,97 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| VIKING THERAPEUTICS | 40,730 | +0,17 % | AKTIEN IM FOKUS: Novo Nordisk sacken nach Daten ab - Gerresheimer schwach | KOPENHAGEN/FRANKFURT/NEW YORK (dpa-AFX) - Enttäuschende Studienergebnisse haben dem dänischen Pharmakonzern Novo Nordisk am Freitag den höchsten Kursverlust in seiner Geschichte eingebrockt. Die Papiere... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | -0,99 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GALAPAGOS NV | 25,780 | -0,62 % | Galapagos NV: Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma | Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96%... ► Artikel lesen | |
| AFFIMED | 1,110 | -3,90 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,262 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,740 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,020 | -2,21 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| CYTOKINETICS | 46,800 | -0,43 % | Cytokinetics, Incorporated: Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy | SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| SPERO THERAPEUTICS | 0,895 | +1,02 % | What 4 Analyst Ratings Have To Say About Spero Therapeutics |
Das Unternehmen CENTURY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,025 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.
